Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Cell & Tissue Engineering

Neutralizing antibodies targeting SARS-CoV-2 spike protein

Shi Xiaojie et al.

Summary: Since it was first identified in Wuhan, China at the end of 2019, SARS-CoV-2 causing the worldwide pandemic has dramatically changed people's lives in multiple aspects. Efforts to curb the progression of the pandemic are urgently ongoing, with promising therapeutic antibodies being developed through various approaches. Studies have shown that neutralizing antibodies against SARS-CoV-2 are mainly targeting the RBD and some non-RBD domains, with convergent germline genes identified for effective antibodies.

STEM CELL RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Einav G. Levin et al.

Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Serre-Yu Wong et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System

Nabeel Khan et al.

Summary: In a nationwide cohort of patients with IBD, vedolizumab and corticosteroids were associated with an increased risk of SARS-CoV-2 infection. Except for corticosteroids, no medications including mesalazine were associated with an increased risk of severe COVID-19.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Nicholas A. Kennedy et al.

Summary: The study found that patients with inflammatory bowel disease treated with infliximab had attenuated serological responses to SARS-CoV-2 infection. Additionally, the serological response to SARS-CoV-2 infection in the infliximab-treated group was further blunted by concomitant use of immunomodulators.

GUT (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Review Gastroenterology & Hepatology

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis

Fatema Alrashed et al.

Summary: Corticosteroids and 5-ASA therapy for IBD were associated with an increased risk of severe COVID-19 outcomes, while anti-TNFs and ustekinumab were linked to favorable outcomes. Other IBD therapies like immunomodulators, tofacitinib, and vedolizumab did not show a significant association with severe disease.

BMJ OPEN GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study

Antoine Meyer et al.

Summary: The study compared the risk of severe COVID-19 among patients with inflammatory bowel disease (IBD) on different medications and found that immunomodulators and biologics do not appear to increase the severity of COVID-19 infection in this population.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 A Prospective Cohort Study

Parakkal Deepak et al.

Summary: Patients with CID show immune response to mRNA-based SARS-CoV-2 vaccines, but some may have lower antibody levels, especially those receiving glucocorticoids and B-cell depletion therapy. Further studies are needed to confirm these preliminary findings.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications

Nabeel Khan et al.

Summary: The study found that full vaccination against SARS-CoV-2 has an effectiveness of approximately 80.4% in patients with inflammatory bowel disease who may be taking immunosuppressive medications.

GASTROENTEROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Human IgG and IgA responses to COVID-19 mRNA vaccines

Adam Wisnewski et al.

Summary: Study on 4 subjects showed that COVID-19 mRNA vaccines effectively induce spike antigen-specific IgG and IgA, but there are marked differences in their persistence in serum.

PLOS ONE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

ANTI-SPIKE S1 IGA, ANTI-SPIKE TRIMERIC IGG, AND ANTI-SPIKE RBD IGG RESPONSE AFTER BNT162B2 COVID-19 MRNA VACCINATION IN HEALTHCARE WORKERS

Gian Luca Salvagno et al.

Summary: The study found that mRNA COVID-19 vaccination leads to sustained serum levels of anti-spike trimeric IgG and anti-spike RBD IgG, along with a modest but significant increase in anti-spike S1 IgA levels. Age was inversely associated with the overall increase of anti-spike trimeric IgG and anti-spike S1 IgA, but not with anti-spike RBD IgG levels.

JOURNAL OF MEDICAL BIOCHEMISTRY (2021)

Add to Collection

Article Gastroenterology & Hepatology